Evidence map›Paper›PMID 18711192›Full record

ReviewJournal of clinical oncology : official journal of the American Society of Clinical Oncology2008

New technologies for human cancer imaging.

John V Frangioni

Registry-linked trialOpen access · greenAbstract readReview
In one paragraph

Review in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02142244 (Infrared Fluorescence Guided Surgery for Sentinel Node Identification in Cutaneous Melanoma), which is not on this map. Cited by 295 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
295citing papers in PubMed, 5 pooled it
28.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02142244 naunknown statusnot on this mapstarted 2014, after this paper: background citation

Infrared Fluorescence Guided Surgery for Sentinel Node Identification in Cutaneous Melanoma

TypeinterventionalSponsorBarretos Cancer HospitalRan2014 to 2021Enrolled318ConditionsMelanoma, Lymph Node MetastasisArmsNear infra red sentinel node biopsy, Indocyanine green, Intraoperative Near-Infrared Imaging System
3 · Its place in the literature

Who cites it

295 citing papers in PubMed, 5 syntheses or guidelines pooled it, 794 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. The clinical usefulness of optical coherence tomography during cancer interventions.Journal of cancer research and clinical oncology · 2018
    Pooled it
  5. Pooled it
  6. Evaluating the prognostic impact of multipleEuropean journal of nuclear medicine and molecular imaging · 2026
    Trial
  7. Trial
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Observational
  20. Article

235 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

John V FrangioniBeth Israel Deaconess Medical Center, 330 Brookline Ave, Rm SL-B05, Boston, MA 02215, USA. jfrangio@bidmc.harvard.edu
Beth Israel Deaconess Medical Center · US

Funding

Intraoperative Near-Infrared Fluorescence ImagingR01CA115296 · NCI · CURADEL, LLC · PI FRANGIONI, JOHN V · 2005 to 2014
$13.9M
Objective Flap Assessment During Reconstructive SurgeryR01EB005805 · NIBIB · BETH ISRAEL DEACONESS MEDICAL CENTER · PI FRANGIONI, JOHN V · 2006 to 2009
$1.5M
Spatially Modulated Near-Infrared Light for Image-Guided Cancer SurgeryR21CA129758 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI FRANGIONI, JOHN V · 2007 to 2009
$1.1M
Near-Infrared Quantum Dots for In Vivo ImagingR21EB000673 · NIBIB · BETH ISRAEL DEACONESS MEDICAL CENTER · PI FRANGIONI, JOHN V · 2002 to 2002
$217k
NCI NIH HHS R01-CA-115296NCI NIH HHS R21-CA-129758NIBIB NIH HHS R01-EB-005805NIBIB NIH HHS R21/R33-EB-000673
6 · The paper itself

Abstract

Despite technical advances in many areas of diagnostic radiology, the detection and imaging of human cancer remains poor. A meaningful impact on cancer screening, staging, and treatment is unlikely to occur until the tumor-to-background ratio improves by three to four orders of magnitude (ie, 10(3)- to 10(4)-fold), which in turn will require proportional improvements in sensitivity and contrast agent targeting. This review analyzes the physics and chemistry of cancer imaging and highlights the fundamental principles underlying the detection of malignant cells within a background of normal cells. The use of various contrast agents and radiotracers for cancer imaging is reviewed, as are the current limitations of ultrasound, x-ray imaging, magnetic resonance imaging (MRI), single-photon emission computed tomography, positron emission tomography (PET), and optical imaging. Innovative technologies are emerging that hold great promise for patients, such as positron emission mammography of the breast and spectroscopy-enhanced colonoscopy for cancer screening, hyperpolarization MRI and time-of-flight PET for staging, and ion beam-induced PET scanning and near-infrared fluorescence-guided surgery for cancer treatment. This review explores these emerging technologies and considers their potential impact on clinical care. Finally, those cancers that are currently difficult to image and quantify, such as ovarian cancer and acute leukemia, are discussed.

Indexed as

Diagnostic ImagingHumansNeoplasms

Identifiers

PMID18711192
PMCPMC2654310
OpenAlexW2145342077

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.